Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2017-02-01 Director's Dealing
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2017-02-01 English
PRIMARY DOCUMENT
Director's Dealing
2017-01-27 English
4 Filing
Director's Dealing
2017-01-27 English
Regulatory Filings 2017
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from a company's legal counsel to the SEC staff regarding comments on a Registration Statement on Form S-1. It discusses the registration of shares for resale by a selling stockholder under Rule 415(a)(1)(i) of the Securities Act, focusing on the eligibility of the registration for a shelf offering. The content is regulatory in nature, addressing compliance and disclosure interpretations, and does not contain financial statements, earnings data, or management discussion of financial results. It is not an annual report, earnings release, or any form of financial report but rather a regulatory filing related to securities registration and compliance with SEC rules. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-01-24 English
Board/Management Information 2017
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 17, 2017, for Ritter Pharmaceuticals, Inc. The key content is the appointment of Dr. William M. Merino to the Board of Directors. This is explicitly described under Item 5.02, which relates to the departure or appointment of directors or certain officers. There is no financial data or report content, only an announcement of a board member change. Therefore, this filing fits the category of Board/Management Information (MANG). The document length is 4440 characters, which is consistent with a typical 8-K announcement rather than a full report. Hence, the classification is MANG with high confidence.
2017-01-17 English
Capital/Financing Update 2016
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the company, the securities being registered, the offering, risk factors, and other disclosures typical of an IPO or secondary offering registration statement. This is not an annual report, earnings release, or any other financial report type. It is a capital markets filing related to financing and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or a certification.
2016-12-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.